- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Genelux-CEO Zindrick Thomas verkauft Aktien im Wert von 33.497 US-Dollar | 1 | Investing.com Deutsch | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| Mi | Genelux-Regulierungschef verkauft Aktien im Wert von 5.873 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.12. | Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright | 1 | GlobeNewswire (USA) | ||
| 15.11. | Genelux GAAP EPS of -$0.19 beats by $0.01 | 1 | Seeking Alpha | ||
| 29.10. | Guggenheim sees upside in Genelux shares, targets $8 as pivotal cancer trial progresses | 1 | Investing.com | ||
| 22.10. | Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer | 175 | GlobeNewswire (Europe) | - VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small... ► Artikel lesen | |
| 09.10. | Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 04.10. | Genelux announces executive departure | 2 | Investing.com | ||
| 03.10. | Genelux kündigt Abgang einer Führungskraft an | - | Investing.com Deutsch | ||
| 03.10. | GENELUX Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 14.09. | Genelux corp insider sells over $170k in company stock | 1 | Investing.com | ||
| 13.09. | Genelux director Tyree James L sells shares worth over $4,400 | 2 | Investing.com | ||
| 12.09. | Genelux corp insider sells over $196k in company stock | 2 | Investing.com | ||
| 31.08. | Genelux Corp insider sells over $550k in company stock | 3 | Investing.com | ||
| 29.08. | Genelux started at buy by Roth MKM ahead of Olvi-Vec readouts | 5 | Seeking Alpha | ||
| 15.08. | Genelux GAAP EPS of -$0.22 | 1 | Seeking Alpha | ||
| 14.08. | Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates | 259 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| 13.08. | Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds | 2 | Insider Monkey | ||
| 01.08. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| INFLARX | 2,088 | -3,06 % | InflaRx startet Phase-2a-Studie mit INF904 in den USA | InflaRx hat in den USA den ersten Patienten in eine Phase-2a-Studie mit dem oralen C5aR-Inhibitor INF904 aufgenommen. Die Studie untersucht das Medikament bei chronischer spontaner Urtikaria (CSU) und... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,420 | 0,00 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| COHERUS | 1,484 | +2,77 % | Coherus BioSciences, Inc.: Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | ||
| CURIS | 3,020 | +1,34 % | Curis Inc Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Curis Inc (CRIS) released Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's bottom line totaled -$10.09... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,314 | -3,14 % | BioXcel Therapeutics stock hits 52-week low at $0.35 | ||
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ESPERION | 2,140 | +2,59 % | Esperion Therapeutics, Inc.: Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions | - $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt - - New Facility Represents $150... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,585 | +0,86 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK | Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from... ► Artikel lesen | |
| FIBROGEN | 0,340 | -12,00 % | FibroGen Aktie: Vorzeigemodell für Erfolg! | Die FibroGen Aktie verzeichnete am 21. Dezember 2024 einen beachtlichen Anstieg von 5,13 Prozent und schloss bei 0,41 EUR. Der Biotechnologiekonzern, der sich auf die Entwicklung von Therapeutika für... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| KARYOPHARM | 0,624 | +0,74 % | KPTI stock touches 52-week low at $0.65 amid market challenges |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,080 (+3,65 %) liegt der Kurs bei 2,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.
